Thalidomide in advanced mastocytosis

British Journal of Haematology

Volumn 141, Issue 2, 2008, Pages 249-253

  Damaj, Gandhi ^a   Bernit, Emmanuelle ^b   Ghez, David ^c   Claisse, Jean François ^a   Schleinitz, Nicolas ^b   Harlé, Jean Robert ^b   Canioni, Danielle ^d   Hermine, Olivier ^c  

^a AMIENS UNIVERSITY HOSPITAL   (France)

^b HÔPITAL DE LA CONCEPTION   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Clinical; Mastocytosis; Thalidomide

Indexed keywords

ALPHA INTERFERON; ANTIHISTAMINIC AGENT; PREDNISOLONE; THALIDOMIDE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BONE MARROW BIOPSY; CASE REPORT; CELL INFILTRATION; CONSTIPATION; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERANCE; FATIGUE; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; LOADING DRUG DOSE; MALE; MAST CELL; MYELOFIBROSIS; PRIORITY JOURNAL; REMISSION; SYMPTOM; SYSTEMIC MASTOCYTOSIS; THROMBOCYTE COUNT;

AGED; ANGIOGENESIS INHIBITORS; BONE MARROW CELLS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MASTOCYTOSIS, SYSTEMIC; MIDDLE AGED; THALIDOMIDE;

EID: 40949134736     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07038.x     Document Type: Article

References (14)

1. Aichberger, K.J., Mayerhofer, M., Gleixner, K.V., Krauth, M.T., Gruze, A., Pickl, W.F., Wacheck, V., Selzer, E., Mullauer, L., Agis, H., Sillaber, C. Valent, P. (2007) Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412. Blood, 109, 3031 3041.
2. Canepa, L., Ballerini, F., Varaldo, R., Quintino, S., Reni, L., Clavio, M., Miglino, M., Pierri, I. Gobbi, M. (2001) Thalidomide in agnogenic and secondary myelofibrosis. British Journal Haematology, 115, 313 315.
3. Droogendijk, H.J., Kluin-Nelemans, H.J., van Doormaal, J.J., Oranje, A.P., van de Loosdrecht, A.A. van Daele, P.L. (2006) Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial. Cancer, 107, 345 351.
4. Florian, S., Esterbauer, H., Binder, T., Mullauer, L., Haas, O.A., Sperr, W.R., Sillaber, C. Valent, P. (2006) Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib. Leukemia Research, 30, 1201 1205. Epub 2006 Jan 1206.
5. Gleixner, K.V., Mayerhofer, M., Aichberger, K.J., Derdak, S., Sonneck, K., Bohm, A., Gruze, A., Samorapoompichit, P., Manley, P.W., Fabbro, D., Pickl, W.F., Sillaber, C. Valent, P. (2006) PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood, 107, 752 759.
6. Hauswirth, A.W., Simonitsch-Klupp, I., Uffmann, M., Koller, E., Sperr, W.R., Lechner, K. Valent, P. (2004) Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. Leukemia Research, 28, 249 257.
7. Kluin-Nelemans, H.C., Oldhoff, J.M., Van Doormaal, J.J., Van 't Wout, J.W., Verhoef, G., Gerrits, W.B., van Dobbenburgh, O.A., Pasmans, S.G. Fijnheer, R. (2003) Cladribine therapy for systemic mastocytosis. Blood, 102, 4270 4276. Epub 2003 Aug 4221.
8. Mesa, R.A., Elliott, M.A., Schroeder, G. Tefferi, A. (2004) Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia. Mayo Clinic Proceedings, 79, 883 889.
9. Pardanani, A., Hoffbrand, A.V., Butterfield, J.H., Tefferi, A., Tefferi, A. Pardanani, A. (2004) Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine. Clinical, genetic, and therapeutic insights into systemic mast cell disease. Leukemia Research, 28, 127 131.
10. Pardanani, A., Akin, C. Valent, P. (2006) Pathogenesis, clinical features, and treatment advances in mastocytosis. Best Practice & Research. Clinical Haematology, 19, 595 615.
11. Valent, P., Horny, H.P., Escribano, L., Longley, B.J., Li, C.Y., Schwartz, L.B., Marone, G., Nunez, R., Akin, C., Sotlar, K., Sperr, W.R., Wolff, K., Brunning, R.D., Parwaresch, R.M., Austen, K.F., Lennert, K., Metcalfe, D.D., Vardiman, J.W. Bennett, J.M. (2001) Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leukemia Research, 25, 603 625.
12. Valent, P., Ghannadan, M., Akin, C., Krauth, M.T., Selzer, E., Mayerhofer, M., Sperr, W.R., Arock, M., Samorapoompichit, P., Horny, H.P. Metcalfe, D.D. (2004) On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts. European Journal of Clinical Investigation, 34 (Suppl. 2 41 52.
13. Valent, P., Akin, C., Escribano, L., Fodinger, M., Hartmann, K., Brockow, K., Castells, M., Sperr, W.R., Kluin-Nelemans, H.C., Hamdy, N.A., Lortholary, O., Robyn, J., van Doormaal, J., Sotlar, K., Hauswirth, A.W., Arock, M., Hermine, O., Hellmann, A., Triggiani, M., Niedoszytko, M., Schwartz, L.B., Orfao, A., Horny, H.P. Metcalfe, D.D. (2007) Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. European Journal of Clinical Investigation, 37, 435 453.
14. Vardiman, J.W., Harris, N.L. Brunning, R.D. (2002) The World Health Organization (WHO) classification of the myeloid neoplasms. Blood, 100, 2292 2302.